West Pharmaceutical Services (WST) Receivables (2009 - 2026)

West Pharmaceutical Services has disclosed Receivables across 18 years of filings, most recently posting $712.0 million for Q2 2026.

• In Q2 2026, Receivables rose 22.25% year-over-year to $712.0 million; the TTM figure through Jun 2026 stood at $712.0 million (up 22.25% YoY), while the FY2025 annual figure was $586.3 million, up 1.82% from the prior year.
• Receivables came in at $712.0 million for Q2 2026 at West Pharmaceutical Services, up from $685.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $712.0 million in Q2 2026 to a low of $479.4 million in Q2 2024.
• Average Receivables over 5 years is $553.3 million, with a median of $530.9 million recorded in 2022.
• Year-over-year, Receivables declined 10.29% in 2024 and grew 26.12% in 2026.
• Over 5 years, Receivables stood at $507.4 million in 2022, then advanced by 5.14% to $533.5 million in 2023, then increased by 7.93% to $575.8 million in 2024, then gained by 1.82% to $586.3 million in 2025, then gained by 21.44% to $712.0 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $712.0 million in Q2 2026, $685.6 million in Q1 2026, and $586.3 million in Q4 2025.